Anaplastic lymphoma kinase enhances Wnt signaling through R-spondin: A new dimension to ALK-mediated oncogenesis.

in International journal of biological macromolecules by Kajal Sandhu, Sibasis Sahoo, Arockiasamy Arulandu, S Chockalingam

TLDR

  • ALK, a protein involved in cancer progression, interacts with R-spondins to enhance Wnt signaling, providing new insights into ALK-mediated oncogenesis and potential therapeutic strategies.

Abstract

Anaplastic lymphoma kinase receptor (ALK) is a receptor tyrosine kinase that plays a key role in the progression of several cancers and is activated by ligands such as ALKAL1 and ALKAL2. To identify additional molecules that interact with ALK, we constructed comprehensive genetic and molecular level networks. Notably, our study identified R-spondins, growth factors known to enhance Wnt signaling, as novel interacting partners of ALK. Protein-protein docking studies revealed that R-spondins bind to the TNF-like and EGF-like domains of ALK, which are critical for the interaction of ALK with its known ligand ALKAL2. These docking outcomes were further validated by molecular dynamics simulations, and approximate binding affinity calculations that confirmed the stability and conformational behavior of the ALK and R-spondin complex. These in silico findings indicate a strong interaction between ALK and R-spondins. To investigate whether this interaction influences Wnt signaling in vitro, we conducted a Wnt signaling reporter assay (TOP Flash/FOP Flash) in neuroblastoma cells by introducing Rspo2, Wnt3a, and crizotinib, an ALK inhibitor. The results showed a decrease in the TOP/FOP ratio when ALK was inhibited. Collectively, our study reveals a novel role for ALK in enhancing Wnt signaling via R-spondins, providing new dimension into ALK-mediated oncogenesis.

Overview

  • The study aimed to identify novel molecules that interact with Anaplastic Lymphoma Kinase Receptor (ALK) and its role in cancer progression.
  • ALK is a key receptor tyrosine kinase involved in the progression of several cancers and is activated by ligands such as ALKAL1 and ALKAL2.
  • The study constructed comprehensive genetic and molecular level networks to identify interacting partners of ALK, leading to the identification of R-spondins as novel interacting partners of ALK.

Comparative Analysis & Findings

  • Protein-protein docking studies revealed that R-spondins bind to the TNF-like and EGF-like domains of ALK, which are critical for the interaction of ALK with its known ligand ALKAL2.
  • Molecular dynamics simulations and approximate binding affinity calculations confirmed the stability and conformational behavior of the ALK and R-spondin complex.
  • Wnt signaling reporter assays (TOP Flash/FOP Flash) in neuroblastoma cells showed a decrease in TOP/FOP ratio when ALK was inhibited, indicating that ALK enhances Wnt signaling via R-spondins.

Implications and Future Directions

  • The study provides new insights into ALK-mediated oncogenesis and suggests that targeting ALK may have therapeutic potential in treating cancers.
  • Future studies can explore the role of R-spondins in ALK-mediated Wnt signaling and its implications in cancer development and progression.
  • Understanding the ALK-R-spondin interaction may also provide novel therapeutic strategies for treating Wnt-related diseases and disorders.